紫杉醇脂质体与表柔比星联合治疗晚期乳腺癌的效果研究

Study on the Effect of Paclitaxel Liposome and Epirubicin in the Treatment of Advanced Breast Cancer

目的探讨紫杉醇脂质体与表柔比星联合治疗晚期乳腺癌的效果。方法方便选择2016年12月-2019年11月该院收治的60例晚期乳腺癌患者作为研究对象,以随机数字表法将其随机分为两组,其中对照组与研究组,各30例。对照组采用表柔比星+环磷酰胺化疗方案,研究组采用表柔比星+紫杉醇脂质体化疗方案。对比两组患者的近期疗效、化疗不良反应,以及治疗前后血清肿瘤标志物糖类抗原199(CA199)、糖类抗原125(CA125)与癌胚抗原(CEA)的变化。结果研究组治疗的总有效率为80.00%,高于对照组53.33%,差异有统计学意义(χ^(2)=4.800,P<0.05)。研究组血液系统毒性、外周神经系统毒性、消化系统毒性、其他毒性的发生率6.67%、10.00%、26.67%、6.67%与对照组10.00%、10.00%、23.33%、10.00%对比差异无统计学意义(χ^(2)=0.000、0.000、0.089、0.000,P>0.05)。治疗后,研究组CA199(10.3±3.2)U/mL、CA125(20.6±5.6)U/mL、CEA(3.8±0.5)g/L水平均低于对照组(24.5±6.5)U/mL、(42.5±6.6)U/mL、(5.8±0.6)g/L,差异有统计学意义(t=10.735、13.858、14.026,P<0.01)。结论紫杉醇脂质体与表柔比星联合治疗晚期乳腺癌效果确切,适于临床推广。

Objective To investigate the effect of paclitaxel liposome and epirubicin in the treatment of advanced breast cancer.Methods Sixty patients with advanced breast cancer admitted to the hospital from December 2016 to November2019 were conveniently selected as the research objects,and they were randomly divided into two groups by random number table method,of which the control group and the study group had 30 cases each.The control group used epirubicin+cyclophosphamide chemotherapy,and the study group used epirubicin+paclitaxel liposome chemotherapy.The short-term efficacy,adverse reactions to chemotherapy,and changes in serum tumor markers carbohydrate antigen 199(CA199),carbohydrate antigen 125(CA125)and carcinoembryonic antigen(CEA)before and after treatment were compared between the two groups.Results The total effective rate of treatment in the study group was 80.00%,which was higher than 53.33%in the control group,the difference was statistically significant(χ^(2)=4.800,P<0.05).The incidence of hematological system toxicity,peripheral nervous system toxicity,digestive system toxicity,and other toxicities in the study group 6.67%,10.00%,26.67%,and 6.67%compared with the control group 10.00%,10.00%,23.33%,and 10.00%,there was no statistically significant difference(χ^(2)=0.000,0.000,0.089,0.000,P>0.05).After treatment,the CA199(10.3±3.2)U/mL,CA125(20.6±5.6)U/mL,and CEA(3.8±0.5)g/L levels of the study group were lower than those of the control group(24.5±6.5)U/mL,(42.5±6.6)U/mL,(5.8±0.6)g/L,the difference was statistically significant(t=10.735,13.858,14.026,P<0.01).Conclusion The combination of paclitaxel liposome and epirubicin is effective in the treatment of advanced breast cancer,which is suitable for clinical promotion.